OpenAI has introduced GPT-Rosalind, a reasoning model tailored for the life sciences. It's designed to help researchers move faster from hypothesis to experiment. Access is tightly controlled for now.
The model is named after chemist Rosalind Franklin, whose work helped uncover the structure of DNA. The name fits the mission: GPT-Rosalind is built to tackle problems in the biosciences, drug discovery, and translational medicine. It's meant to help researchers synthesize evidence, generate hypotheses, plan experiments, and work through multi-step research tasks.
OpenAI says the model sets itself apart from earlier GPT versions by being tuned specifically for scientific workflows. It's meant to reason more accurately about molecules, proteins, genes, signaling pathways, and disease biology, while making better use of scientific tools and databases across multi-step workflows. Supported tasks include literature research, interpreting sequence-function relationships, experiment planning, and data analysis.
In OpenAI's own evaluations, GPT-Rosalind outperforms its predecessors GPT-5, GPT-5.2, and GPT-5.4 across chemistry, biochemistry and protein understanding, phylogenetics, experiment design, and tool usage.
